SrasV1, 2020, Analysis, bibRecord, 000034

[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].

Identifieur interne : 000034 ( 2020/Analysis ); précédent : 000033; suivant : 000035

[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].

Auteurs : Y. Shi [République populaire de Chine] ; N. Wang [République populaire de Chine] ; Q M Zou [République populaire de Chine]

Source :

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] [ 0253-9624 ] ; 2020.

RBID : pubmed:32234130

Abstract

The outbreak of 2019 novel coronavirus (2019-nCoV) infection poses a serious threat to global public health. Vaccination is an effective way to prevent the epidemic of the virus. 2019-nCoV along with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) belong to the same β-genus of coronavirus family. Base on the previous experience and the technical platform of developing SARS-CoV and MERS-CoV vaccines, scientists from all over the world are working hard and quickly on the related fields. There are substantial progress in these fields including the characterizing the 2019-nCoV virus, identification of candidate antigens and epitopes, establishment of animal models, characterizing the immune responses, and the design of vaccines. The development of 2019-nCoV vaccines cover all types: inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, et al. As of March 2020, two 2019-nCoV vaccines have entered phase I clinical trials. One is named as Ad5-nCoV developed by the Chinese Institute of Biotechnology of the Academy of Military Medical Sciences and Tianjin Cansino Biotechnology Inc. Ad5-nCoV is based on the replication-defective adenovirus type 5 as the vector to express 2019-nCoV spike protein. The another vaccine is mRNA-1273 developed by the National Institute of Allergy and Infectious Diseases and Moderna, Inc.. RNA-1273 is an mRNA vaccine expressing 2019-nCoV spike protein. Although the rapid development of 2019-nCoV vaccine, it still faces many challenges with unknown knowledge, including the antigenic characteristics of the 2019-nCoV, the influence of antigenic variation, the protective immune response of host, the protection of the elderly population, and the downstream manufacturing process of the new vaccine. The safety and efficacy of vaccines are the first priority for vaccine development and should be carefully evaluated.

DOI: 10.3760/cma.j.cn112150-20200317-00366
PubMed: 32234130

Affiliations:

République populaire de Chine

Links to Exploration step

pubmed:32234130

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].</title>
<author><name sortKey="Shi, Y" sort="Shi, Y" uniqKey="Shi Y" first="Y" last="Shi">Y. Shi</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041</wicri:regionArea>
<wicri:noRegion>Chengdu 610041</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wang, N" sort="Wang, N" uniqKey="Wang N" first="N" last="Wang">N. Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041</wicri:regionArea>
<wicri:noRegion>Chengdu 610041</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zou, Q M" sort="Zou, Q M" uniqKey="Zou Q" first="Q M" last="Zou">Q M Zou</name>
<affiliation wicri:level="1"><nlm:affiliation>National Engineering Research Center of Immunological Products, Army Medical University, Chongqing 400038, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>National Engineering Research Center of Immunological Products, Army Medical University, Chongqing 400038</wicri:regionArea>
<wicri:noRegion>Chongqing 400038</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32234130</idno>
<idno type="pmid">32234130</idno>
<idno type="doi">10.3760/cma.j.cn112150-20200317-00366</idno>
<idno type="wicri:Area/PubMed/Corpus">000420</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000420</idno>
<idno type="wicri:Area/PubMed/Curation">000420</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000420</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000018</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000018</idno>
<idno type="wicri:Area/Ncbi/Merge">003671</idno>
<idno type="wicri:Area/Ncbi/Curation">003671</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003671</idno>
<idno type="wicri:doubleKey">0253-9624:2020:Shi Y:progress:and:challenge</idno>
<idno type="wicri:Area/Main/Merge">000033</idno>
<idno type="wicri:Area/Main/Curation">000034</idno>
<idno type="wicri:Area/Main/Exploration">000034</idno>
<idno type="wicri:Area/2020/Extraction">000034</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].</title>
<author><name sortKey="Shi, Y" sort="Shi, Y" uniqKey="Shi Y" first="Y" last="Shi">Y. Shi</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041</wicri:regionArea>
<wicri:noRegion>Chengdu 610041</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wang, N" sort="Wang, N" uniqKey="Wang N" first="N" last="Wang">N. Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041</wicri:regionArea>
<wicri:noRegion>Chengdu 610041</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zou, Q M" sort="Zou, Q M" uniqKey="Zou Q" first="Q M" last="Zou">Q M Zou</name>
<affiliation wicri:level="1"><nlm:affiliation>National Engineering Research Center of Immunological Products, Army Medical University, Chongqing 400038, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>National Engineering Research Center of Immunological Products, Army Medical University, Chongqing 400038</wicri:regionArea>
<wicri:noRegion>Chongqing 400038</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]</title>
<idno type="ISSN">0253-9624</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The outbreak of 2019 novel coronavirus (2019-nCoV) infection poses a serious threat to global public health. Vaccination is an effective way to prevent the epidemic of the virus. 2019-nCoV along with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) belong to the same β-genus of coronavirus family. Base on the previous experience and the technical platform of developing SARS-CoV and MERS-CoV vaccines, scientists from all over the world are working hard and quickly on the related fields. There are substantial progress in these fields including the characterizing the 2019-nCoV virus, identification of candidate antigens and epitopes, establishment of animal models, characterizing the immune responses, and the design of vaccines. The development of 2019-nCoV vaccines cover all types: inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, et al. As of March 2020, two 2019-nCoV vaccines have entered phase I clinical trials. One is named as Ad5-nCoV developed by the Chinese Institute of Biotechnology of the Academy of Military Medical Sciences and Tianjin Cansino Biotechnology Inc. Ad5-nCoV is based on the replication-defective adenovirus type 5 as the vector to express 2019-nCoV spike protein. The another vaccine is mRNA-1273 developed by the National Institute of Allergy and Infectious Diseases and Moderna, Inc.. RNA-1273 is an mRNA vaccine expressing 2019-nCoV spike protein. Although the rapid development of 2019-nCoV vaccine, it still faces many challenges with unknown knowledge, including the antigenic characteristics of the 2019-nCoV, the influence of antigenic variation, the protective immune response of host, the protection of the elderly population, and the downstream manufacturing process of the new vaccine. The safety and efficacy of vaccines are the first priority for vaccine development and should be carefully evaluated.</div>
</front>
</TEI>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
</list>
<tree><country name="République populaire de Chine"><noRegion><name sortKey="Shi, Y" sort="Shi, Y" uniqKey="Shi Y" first="Y" last="Shi">Y. Shi</name>
</noRegion>
<name sortKey="Wang, N" sort="Wang, N" uniqKey="Wang N" first="N" last="Wang">N. Wang</name>
<name sortKey="Zou, Q M" sort="Zou, Q M" uniqKey="Zou Q" first="Q M" last="Zou">Q M Zou</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/2020/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000034 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000034 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    2020
   |étape=   Analysis
   |type=    RBID
   |clé=     pubmed:32234130
   |texte=   [Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i   -Sk "pubmed:32234130" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].

[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.